This multi-center, prospective, observational study will describe the management of relapsing or refractory chronic lymphocytic leukemia (CLL) patients. Data will be collected for 2 years.
Study Type
OBSERVATIONAL
Enrollment
327
Chemotherapy regimens associated with MabThera/Rituxan in management of relapse/refractory CLL: Percentage of patients receiving purine analogues/bendamustine/alkylating agents/other chemotherapy
Time frame: 2 years
Overall response rate
Time frame: 2 years
Complete response rate
Time frame: 2 years
Progression-free survival
Time frame: 2 years
Time to next treatment
Time frame: 2 years
Overall survival
Time frame: 2 years
Safety (incidence of adverse events)
Time frame: 2 years
Safety (incidence of hematologic adverse events)
Time frame: 2 years
Safety (incidence of infections)
Time frame: 2 years
Safety (incidence of secondary malignancies)
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Aix-en-Provence, France
Unnamed facility
Aix-en-Provence, France
Unnamed facility
Albi, France
Unnamed facility
Angers, France
Unnamed facility
Antibes, France
Unnamed facility
Argenteuil, France
Unnamed facility
Arras, France
Unnamed facility
Avignon, France
Unnamed facility
Bayonne, France
Unnamed facility
Béziers, France
...and 74 more locations